A Study Evaluating the Efficacy and Safety of Novel Non-Opioid SRP-001 in Acute Pain After Molar Extraction
A Phase 2 Randomized, Double-blind, Placebo-controlled Study Assessing Analgesic Efficacy and Safety of the Novel Non-opioid SRP-001 Compared to Placebo in Patients With Moderate-to-severe Acute Postoperative Pain After Impacted Third Mandibular Molar Extraction
This study tests whether a single oral dose of SRP-001 (2,000 mg), a non-opioid drug, relieves moderate-to-severe pain after surgery to remove impacted third molars (wisdom teeth), compared with placebo. It also evaluates safety and how the body processes the drug.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
This is a single-center, randomized, double-blind, placebo-controlled, parallel-group Phase 2 study evaluating the analgesic efficacy, onset of action, pharmacokinetics, and safety of a single oral dose of SRP-001 (2,000 mg oral suspension) compared to matching placebo in 130 adult participants experiencing moderate-to-severe acute postoperative pain (NPRS ≥ 5 and categorical pain ≥ 2 within 4.5 hours) following extraction of two or more third molars (including at least two bone-impacted mandibular molars). Participants remain in the clinical research unit for 12 hours post-dose for serial efficacy, double-stopwatch onset, safety, and pharmacokinetic assessments, followed by 24-hour rescue diary tracking (two-tiered rescue: ibuprofen 400 mg, then oxycodone 5 mg if needed) and an in-person safety follow-up visit on Day 8 (± 2 days).
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Todd Bertoch, MD
- Número de teléfono: 928 830 7354
- Correo electrónico: t.bertoch@cenexel.com
Copia de seguridad de contactos de estudio
- Nombre: CenExel JBR Recruiting
Ubicaciones de estudio
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84107
- CenExel JBR Clinical Research
-
Contacto:
- Todd M Burtoch, MD
- Número de teléfono: 2303 (801) 261-2000
- Correo electrónico: t.bertoch@cenexel.com
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Is male or female ≥ 18 and ≤ 50 years of age.
- Requires extraction of 2 or more third molars. At least 2 of the third molars must be a fully or partially bone impacted mandibular molar.
- Experiences moderate-to-severe pain defined as a score ≥ 2 on the 4-point categorical scale, and a score of ≥ 5 measured by the 0-10 Numeric Pain Rating Scale (NPRS) within 4.5 hours after surgery.
- Has a body weight ≥ 45 kg and a body mass index (BMI) ≤ 35 kg/m2.
- Female subjects of child-bearing potential must have used an acceptable method of contraception for at least 30 days prior to randomization and agree to continue use until at least 48 hours post-discharge from the clinic. To be considered not of child-bearing potential, females must be surgically sterile (defined as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or post-menopausal (defined as no menses for 12 months without an alternative medical cause).
- Free of clinically significant abnormal findings as determined by medical history, physical examination, vital signs, and laboratory tests.
- Able to provide written informed consent.
- Is willing and able to comply with study requirements (including diet and smoking restrictions), complete the pain evaluations, remain at the study site for 12 hours post-dose on Day 1, and complete an in-person follow-up visit on Day 8 (± 2 days)
Exclusion Criteria:
- Known hypersensitivity or allergy to acetaminophen, NSAIDs (including ibuprofen), aspirin, study drug ingredients, anesthetics, or antibiotics.
- History of active or previous peptic ulceration, gastrointestinal bleeding or perforation, heart failure, renal impairment, uncontrolled hypertension, exercise-induced asthma, nasal polyps, or chronic rhinitis; or history or presence of hepatic impairment, or clinically significant baseline laboratory abnormalities at Screening, defined as serum ALT or AST > 1.5× the Upper Limit of Normal (ULN), or total bilirubin > 1.5× ULN (unless attributable to documented Gilbert's syndrome), uncontrolled hypertension, exercise-induced asthma, nasal polyps, or chronic rhinitis.
- Complications from tooth extraction resulting in a "severe" surgical trauma rating.
- Dental surgery within 60 days prior to Day 1.
- Positive urine drug screen or alcohol breathalyzer test.
- Positive pregnancy test (serum at screening, urine pre-surgery on Day 1) or lactating.
- Known history or suspected (in the opinion of the investigator) of alcoholism or drug abuse within 2 years.
- Concomitant medications that confound pain assessment. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) are permitted if on a stable dose for ≥ 4 weeks prior to Screening.
- History of chronic use (defined as daily use for > 2 weeks within 6 months) of NSAIDs, opiates, or glucocorticoids for any condition within 6 months prior to dosing.
- Difficulty swallowing oral medication.
- Investigational drug exposure within 30 days or 5 half-lives.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: SRP-001
SRP-001 Single Oral Suspension dose of 2,000 mg |
SRP-001 Oral Suspension |
|
Comparador de placebos: Matching Placebo for SRP-001
Matching Placebo for SRP-001 Oral Suspension |
Matching Placebo for SRP-001 Oral Suspension
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Sum of Pain Intensity Differences Over 0 to 6 Hours (SPID0-6)
Periodo de tiempo: 0 to 6 hours post-dose
|
Time-weighted sum of pain intensity differences from baseline over 0 to 6 hours post-dose, assessed using the 0-10 Numeric Pain Rating Scale (NPRS scale 0 -10 higher being worse) comparing SRP-001 (2,000 mg) to placebo. |
0 to 6 hours post-dose
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time-Weighted Sum of Pain Intensity Differences Over 0 to 2, 0 to 4, and 0 to 8 Hours (SPID0-2, SPID0-4, SPID0-8)
Periodo de tiempo: 0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose
|
Time-weighted sum of pain intensity differences from baseline over 0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose assessed on the 0-10 NPRS (higher being worse) |
0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose
|
|
Sum of pain relief (TOTPAR)
Periodo de tiempo: O to 2, 0 to 4, 0 to 6 and 0-8 hours.
|
Sum of pain relief (TOTPAR) from 0 to 2 (TOTPAR0-2), 0 to 4 (TOTPAR0-4), 0 to 6 hours (TOTPAR0-6), and 0 to 8 (TOTPAR0-8) post dose. |
O to 2, 0 to 4, 0 to 6 and 0-8 hours.
|
|
Time to a ≥1-Point Reduction in Numeric Pain Rating Scale (T1PMPR)
Periodo de tiempo: 0 to 8 hours post-dose
|
Time from study drug administration to a ≥1-point reduction in pain intensity on the 0-10 NPRS, derived mathematically from scheduled post-dose pain assessments. |
0 to 8 hours post-dose
|
|
Time to a ≥2-Point Reduction in Numeric Pain Rating Scale (T2PMPR)
Periodo de tiempo: 0 to 8 hours post-dose
|
Time from study drug administration to a ≥2-point reduction in pain intensity on the 0-10 NPRS, derived mathematically from scheduled post-dose pain assessments. |
0 to 8 hours post-dose
|
|
Time to first use of rescue medication
Periodo de tiempo: 0 - 6, 0-8, 0-24 hours post dose.
|
Rescue medication time for SRP-001 compared with placebo |
0 - 6, 0-8, 0-24 hours post dose.
|
|
Total rescue medication consumption
Periodo de tiempo: 0 - 6, 0-8, 0-24 hours post dose.
|
Total rescue medication consumption for SRP-001 compared with placebo |
0 - 6, 0-8, 0-24 hours post dose.
|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Periodo de tiempo: Day 1 through Follow-up Visit (Day 8 ± 2 days)
|
Safety as assessed by number of participants with AEs and SAEs for SRP-001 compared with placebo and relationship to study medication |
Day 1 through Follow-up Visit (Day 8 ± 2 days)
|
|
Pain intensity difference (PID) using the 11-point numeric pain rating scale (NPRS)
Periodo de tiempo: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours post-dose
|
Pain intensity difference (PID) Scale is -10 to 10 (higher is better) |
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours post-dose
|
|
Patient's global evaluation of study drug using a 5 point categorical scale
Periodo de tiempo: Up to 6 hours post dose
|
Patient's global evaluation of study drug immediately before the first dose of rescue medication, or at early termination (whichever occurs first) using 5 point scale where 0=poor o 4=excellent |
Up to 6 hours post dose
|
|
Number of participants with clinically significant abnormalities in laboratory abnormalities
Periodo de tiempo: Screening, Day 1 pre-surgery and follow-up visit, Day 8 ± 2
|
Number of participants with laboratory values judged clinically significant by the investigator in the following panels: Liver function tests (ALT, AST, bilirubin, alkaline phosphatase) Renal function tests (creatinine, BUN) Hematology parameters (CBC with differential) |
Screening, Day 1 pre-surgery and follow-up visit, Day 8 ± 2
|
|
Maximum Observed Plasma Concentration (CMax) of SRP-001
Periodo de tiempo: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
CMax of SRP001 following a single 2,000mg oral dose, obtained directly from the plasma concentration data |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Time to maximum observed plasma concentration (Tmax) of SRP-001
Periodo de tiempo: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
Tmax of SRP-001 following a single 2,000mg oral dose, obtained directly from the plasma concentration-time data |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Area under the plasma concentration-time curve from 0-12 hours (AUC0-12) of SRP-001
Periodo de tiempo: Pre-dose through 12 hours post-dose
|
AUC0-12 of SRP-001 following a single 2,000mg oral dose. |
Pre-dose through 12 hours post-dose
|
|
Area under the plasma concentration time curve from time 0 to the last measurable concentration (AUC0-t) of SRP-001
Periodo de tiempo: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
AUC0-t of SRP001 following a single 2,000mg oral dose |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Area under the plasma concentration time curve from time 0 extrapolated to infinity (AUC0-inf) of SRP-001
Periodo de tiempo: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
AUC0-inf of SRP-001 following a single 2,000mg oral dose |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Terminal elimination half life (t 1/2) of SRP-001
Periodo de tiempo: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
t 1/2 of SRP-001 following a single 2,000mg oral dose |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Apparent oral clearance (CL/F) of SRP-001
Periodo de tiempo: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
CL/F of SRP-001 following a single 2,000mg oral dose |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Apparent volume of distribution during the terminal phase (Vx/F) of SRP-001
Periodo de tiempo: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
Vz/F of SRP-001 following a single 2,000mg oral dose |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Pain relief Difference (PR) using the 11-point numeric pain rating scale (NPRS)
Periodo de tiempo: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
Pain relief difference (PR) |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to first perceptible relief and time to confirmed perceptible pain relief
Periodo de tiempo: 0-4.5 hours post dose
|
TPPR and TCPR via stopwatch 1 |
0-4.5 hours post dose
|
|
Time to meaningful relief
Periodo de tiempo: 0-4.5 hours post dose
|
TMPR via Stopwatch 2 |
0-4.5 hours post dose
|
|
Time to complete pain relief
Periodo de tiempo: 0 to 8 hours post-dose
|
TCOMPR, NPRS = 0 |
0 to 8 hours post-dose
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Todd M Bertoch, MD, CenExel JBR Clinical Research
Publicaciones y enlaces útiles
Publicaciones Generales
- Coderch C, Bazan HA, Bazan NG, Surjyadipta B, Alvarez-Builla J, de Pascual-Teresa B. Computational Insights into the Structural Basis for Reduced Hepatotoxicity of Novel Nonopioid Analgesics. ChemMedChem. 2025 Nov 18;20(22):e202500639. doi: 10.1002/cmdc.202500639. Epub 2025 Oct 21.
- Olson AC, Afyusisye F, Egger J, Noyd D, Likonda B, Masalu N, Suneja G, Chao N, Zullig LL, Schroeder K. Cancer incidence and treatment utilization patterns at a regional cancer center in Tanzania from 2008-2016: Initial report of 2,772 cases. Cancer Epidemiol. 2020 Aug;67:101772. doi: 10.1016/j.canep.2020.101772. Epub 2020 Jul 10.
- Bazan HA, Giles BL, Bhattacharjee S, Edwards S, Bazan NG. A non-toxic analgesic elicits cell-specific genomic and epigenomic modulation by targeting the PAG brain region. Neurobiol Pain. 2025 Jul 20;18:100192. doi: 10.1016/j.ynpai.2025.100192. eCollection 2025 Jul-Dec.
- Frelinger AL 3rd, Haynes RL, Goldstein RD, Berny-Lang MA, Gerrits AJ, Riehs M, Haas EA, Paunovic B, Mena OJ, Campman SC, Milne GL, Sleeper LA, Kinney HC, Michelson AD. Dysregulation of platelet serotonin, 14-3-3, and GPIX in sudden infant death syndrome. Sci Rep. 2024 May 15;14(1):11092. doi: 10.1038/s41598-024-61949-9.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- SRP-001-002
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .